Abstract: The invention relates to an ion exchange liquid membrane flow battery. The ion exchange liquid membrane separates the catholyte and anolyte by independently stratifying with the catholyte and anolyte, it dissolves the supporting solute but does not dissolve active material in the catholyte and anolyte. The present invention uses the ion exchange liquid membrane to replace the traditional ion exchange solid membrane, solving the problems of high cost and short life of the latter. In addition, the technical solution of the present invention has significant advantages in preventing the crossover of active material due to the adjustable thickness of the ion exchange liquid membrane. Moreover, the technical solution of the present invention can flexibly match all kinds of acidic, neutral, alkaline aqueous or organic catholyte with anolyte according to application requirements, solving the problem of limited catholyte-anolyte match in a conventional flow battery.

Abstract: This application discloses a LiDAR, an autonomous driving system and a movable device. The LiDAR includes a housing, a light transmitting plate, an emitting component, a receiving component, and a functional board. An emitting board of the emitting component is on one side of an emitting lens that is far away from the light transmitting plate. A receiving board of the receiving component is on one side of a receiving lens that is far away from the light transmitting plate. The functional board is between the emitting board and the emitting lens. The functional board avoids an optical transmission path between the emitting board and the emitting lens. The functional board is in contact with the housing. The heat dissipation efficiency of the LiDAR is improved.

Abstract: Provided is a testing apparatus for friction and wear, which includes a testing mechanism, a controller, a lubrication system, a cooling system, a loading system, and a detection system. The controller is communicatively connected to the testing mechanism. The lubrication system is adapted to be in communication with the testing mechanism and communicatively connected to the controller. The cooling system is adapted to be in communication with the testing mechanism. The loading system is adapted to be in communication with the testing mechanism and communicatively connected to the controller. The detection system is adapted to be connected to the testing mechanism and communicatively connected to the controller.

Abstract: This application discloses a laser ranging device, including a housing, a light-transmitting sheet, at least one laser emission module, and at least one laser receiving module; the laser emission module includes a laser and an emission lens module; the emission lens module includes at least one emission optical element; the laser receiving module includes a laser detector and a receiving lens module; the receiving lens module includes at least one receiving optical element; the laser receiving module also includes a first enclosing member; and the first enclosing member is arranged between a first optical element and the light-transmitting sheet to enclose and form a first sealing cavity between the light-transmitting sheet and the first optical element; or the second enclosing member is arranged between a second optical element and the light-transmitting sheet to enclose and form a second sealed cavity between the light-transmitting sheet and the second optical element.

Abstract: This application discloses an optical system and a LiDAR, where the optical system includes a bracket and at least one first optical assembly; the bracket includes a first end surface and a second end surface that are arranged back to back, where the bracket is also provided with a first accommodation cavity, and the first accommodation cavity extends along a first axial direction and communicates with the first end surface and the second end surface; and the first optical assembly includes at least one optical element, and the optical element included in the first optical assembly is arranged in the first accommodation cavity along the first axial direction, and abuts against an inner wall of the first accommodation cavity.

Abstract: The present disclosure relates to the use of substituted heterocycles for the inhibition of the activity of WIP1. Suitably, the present disclosure relates to the use of substituted heterocycles for the treatment of cancer.

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Abstract: An unmanned aerial vehicle (UAV) base station includes a housing and a UAV fixation system. The housing includes a top-plate configured for a UAV to land on the top-plate. The UAV fixation system is configured to direct the UAV present on the top-plate to a battery-exchange zone of the top-plate.

Abstract: An optical emitting device and an optical sensor are provided. The optical emitting device includes a body, a light source, and a first light-blocking structure. The body has an emitting cavity extending in a first preset direction. The emitting cavity has an incident light port and an emergent light port that are arranged in the first preset direction. An inner wall of the emitting cavity has a first inner wall portion and a second inner wall portion. The first inner wall portion and the second inner wall portion are oppositely arranged. The light source and the body are arranged in the first preset direction. The first light-blocking structure is arranged in the first inner wall portion of the emitting cavity. A light-transmitting channel is arranged between the first light-blocking structure and the second inner wall portion. The first light-blocking structure includes a plurality of first light-blocking sheets.

Abstract: A LiDAR is provided. The LiDAR includes two laser emission modules and one laser receiving module. The two laser emission modules are located separately on opposite sides of the laser receiving module, and a combination of emission fields of view of the two laser emission modules matches a receiving field of view of the laser receiving module.

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Abstract: The present invention discloses an N-alkyl-N-cyanoalkylbenzamide compound of General Formula I, an intermediate of General Formula II used to prepare the compound, wherein R1 is selected from halo or C1-C3 alkyl; R2 is selected from halo or CN; R3 is selected from halo, or C1-C3haloalkyl; R4 is selected from halo; R5 is selected from H or halo; R6 is selected from C1-C3alkyl, C1-C3 haloalkyl or C1-C5 alkoxyalkyl; R7 is selected from C1-C5 alkyl; and R8 is selected from hydrogen or C1-C5alkyl. Compared with the compounds in the prior art, the compound of General Formula I has a higher activity at a low concentration. Particularly, the compound of the present invention still has 60% or higher of the insecticidal activity at a concentration below 1 ppm. This greatly reduces the amount of the compound used and the residue of the compound in farmland, and is thus environmentally friendly.